Eupraxia Pharmac Stock Price, News & Analysis

Eupraxia Pharmaceuticals (TSX/NASDAQ: EPRX) announced positive data from the fifth cohort of its RESOLVE Phase 1b/2a trial for EP-104GI in treating Eosinophilic Esophagitis (EoE). Key highlights include: one patient achieving complete histological remission at 12 weeks, consistent improvement in patient-reported outcomes, and the largest average reduction in symptom scores observed in the fourth cohort at 24 weeks. The fifth cohort showed the greatest percentage change in histology scores to date, with clear dose response across Cohorts 3 to 5. No serious adverse events were reported, and Cohort 6 is fully enrolled with data expected in Q1 2025.

Eupraxia Pharmaceuticals (NASDAQ: EPRX) reported Q3 2024 financial results with a net loss of $6.0 million, compared to $4.9 million in Q3 2023. Cash position stood at $8.7 million as of September 30, 2024. The company announced positive clinical data from its RESOLVE Phase 1b/2a trial for EP-104GI in eosinophilic esophagitis treatment and published Phase 2b SPRINGBOARD trial data in The Lancet Rheumatology. Post-quarter, Eupraxia raised C$44.5 million through a private placement, appointed new executives, and expects funding through Q3 2026.

Eupraxia Pharmaceuticals (TSX/NASDAQ: EPRX) has completed a non-brokered private placement raising C$44.5 million through the issuance of 8,905,638 Series 1 Preferred shares at C$5.00 per share. The proceeds will fund clinical trials for EP104GI, research programs, and general corporate purposes. The company appointed Joseph Freedman, former Brookfield Asset Management executive, to its board. The Preferred Shares rank senior to common shares, are convertible to common shares on a one-to-one basis, and will earn dividends after three years. The company also terminated its C$12 million convertible debt facility.

Eupraxia Pharmaceuticals (TSX/NASDAQ: EPRX) announced its participation at the American College of Gastroenterology Annual Scientific Meeting 2024 in Philadelphia, presenting two significant posters. The first poster (P2209), which received a Presidential Award, focuses on EP-104GI's pharmacokinetics and tolerability in mini-pigs. The second poster (P3911), designated as an 'Abstract of Interest,' presents efficacy and pharmacokinetic results from the RESOLVE Phase 1b/2a study's first four cohorts. Both presentations, scheduled for October 28-29, 2024, showcase the company's work on their extended-release fluticasone formulation for treating Eosinophilic Esophagitis.

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) (TSX: EPRX) announced the publication of its Phase 2b SPRINGBOARD trial data for EP-104IAR in Lancet Rheumatology. The trial evaluated EP-104IAR for knee osteoarthritis treatment. Key findings include:

1. EP-104IAR demonstrated clinically significant and durable pain relief.
2. Minimal changes in glucose and cortisol were observed.
3. Stable fluticasone propionate concentrations in plasma were maintained.

The study involved 318 participants and met its primary endpoint, showing statistically significant improvement over placebo in WOMAC Pain at 12 weeks (p=0.004). Three of four secondary endpoints also showed significant improvement. The results suggest EP-104IAR's potential to become a best-in-class therapy for knee osteoarthritis, which affects over 30 million people in the U.S. alone.

Eupraxia Pharmaceuticals Inc. (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company, has announced its participation in the United European Gastroenterology (UEG) Week 2024 in Vienna, Austria, from October 12-15, 2024. The company will present a poster featuring data from the RESOLVE trial, a Phase 1b/2a dose-escalation study of EP-104GI for Eosinophilic Esophagitis.

The presentation details include:

• Poster Number: PP0584
• Title: Results from Dose Escalation in RESOLVE, an Ongoing Phase 1b/2a Dose-Escalation Study of EP-104GI (Extended-Release Fluticasone Propionate Intra-Esophageal Injection) for Eosinophilic Esophagitis
• Topic: Oesophageal, gastric and duodenal

Eupraxia Pharmaceuticals (TSX: EPRX) (NASDAQ: EPRX) has announced key appointments to strengthen its senior management team. Dr. Amanda Malone, co-founder and former Chief Scientific Officer, has been promoted to Chief Operating and Scientific Officer. Dr. Rahul Sarugaser joins as Executive Vice President of Corporate Development.

Dr. Malone, who co-founded Eupraxia in 2012, has been instrumental in developing the company's DiffuSphere™ technology and leading successful clinical trials. Dr. Sarugaser brings 20 years of experience in capital markets and healthcare, most recently as Managing Director of Equity Research at Raymond James.

Eupraxia is advancing its DiffuSphere™ technology for targeted drug delivery in areas with high unmet medical need. The company's lead product, EP-104GI, is in a Phase 1b/2a trial for eosinophilic esophagitis. Eupraxia recently completed a successful Phase 2b trial of EP-104IAR for knee osteoarthritis pain.

Eupraxia Pharmaceuticals Inc. (TSX: EPRX) (NASDAQ: EPRX) has announced its participation in the 20th International Symposium on Digestive Endoscopy (ISDE) World Congress for Esophageal Diseases in Edinburgh, Scotland, from September 22-24, 2024. The company will present a poster titled 'Initial Results from RESOLVE, a Phase 1b Dose-Escalation Study of EP-104GI (Extended-Release Fluticasone Propionate Intra-Esophageal Injection) for Eosinophilic Esophagitis'.

The presentation, scheduled for September 23, 2024, from 12:00 PM to 1:45 PM BST, will showcase data from cohorts one through four of the RESOLVE trial. It falls under the 'Benign Disease' theme and has been assigned paper number 265. Eupraxia, a clinical-stage biotechnology company, utilizes its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet needs.

Eupraxia Pharmaceuticals (TSX/NASDAQ: EPRX) announced positive data from its RESOLVE Phase 1b/2a trial of EP-104GI for treating eosinophilic esophagitis (EoE). Key findings include:

- 10 of 11 evaluable patients in the first four cohorts experienced reduced symptom scores at 12 weeks

- The fourth cohort showed the greatest percentage change in histology scores to date

- No serious adverse events reported across all four fully-dosed cohorts

The fourth cohort data showed:

- 45% mean reduction in symptom scores at 12 weeks

- 39% mean reduction in histology composite stage scores

- 67% mean reduction in peak eosinophil counts

These results are comparable to currently approved EoE therapies. The company remains optimistic about further improvements as the trial progresses towards optimal dosing.